- Latest news▼
-
12:16, April 19 Scientists grow human mini-lungs in lab
-
10:23, April 19 JAMA Oncology: Urine test can help rule out high-grade prostate cancer with almost 100% accuracy, study shows
-
18:00, April 18 Daily Mail: Elderly woman in China gets infected with brain-eating amoeba
-
14:19, April 18 Obesity: exercising before breakfast helps you lose weight faster
-
10:42, April 18 The Conversation: childhood trauma can cause pathological hoarding
-
08:37, April 18 Daily Mail: Satiating food reduces cravings for sweets, nutritionist says
-
18:22, April 17 First Armenian-German Conference entitled “Heart Failure Spring School”
-
08:38, April 17 Why do kids usually recover from COVID-19 more easily than adults?
-
14:37, April 16 Daily Mail: intermittent fasting is not suitable for children and women before their periods
-
16:41, April 15 Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk
-
15:04, April 15 305 cases of measles recorded in Armenia so far in 2024
-
14:38, April 15 Food and Environmental Virology: tea contributes to effective coronavirus control
-
12:41, April 15 Daily Mail: vitamin A, B3 and E supplements can be dangerous
-
10:56, April 15 Diabetes Care: evening physical activity is good for the heart
-
08:27, April 15 Women are more susceptible to blood loss and death during bypass surgery than men, researchers say
All materials
Oxford COVID-19 vaccine provides 70% efficiency
An experimental COVID-19 vaccine being developed by Oxford University and the British-Swedish company AstraZeneca showed an average efficacy of 70%, the pharmaceutical company reported on its website.
The trials tested two options for administering the AZD1222 vaccine. The first one implies that over 2,700 volunteers have received the vaccine, first in a half dose, and a month later, in a full dose, and the effectiveness of the vaccine was 90%.
During the second option, two full doses were applied. It was tested on 9,000 people, and the effectiveness was only 62%. A combined analysis of both dosing regimens showed an average efficiency of 70%. In September, AstraZeneca suspended trials of its COVID-19 vaccine after one of the study participants contracted transverse myelitis.
Later, in October, one of the volunteers has died in the national trials of the AstraZeneca vaccine. However, it turned out that the test taker received a placebo, not the actual vaccine, and the company continued testing.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Archive
- Most read
month
week
day
- WHO: Nigeria pioneers revolutionary meningitis vaccine 1193
- One-third of women experience menstruation-related migraines, most often during premenopause - study 1192
- Daily Mail: vitamin A, B3 and E supplements can be dangerous 1094
- Food and Environmental Virology: tea contributes to effective coronavirus control 1087
- Cell: in carriers of defective BRCA2 gene, sugar consumption increases cancer risk 1058
- 305 cases of measles recorded in Armenia so far in 2024 1051
- Women are more susceptible to blood loss and death during bypass surgery than men, researchers say 977
- Diabetes Care: evening physical activity is good for the heart 932
- Daily Mail: intermittent fasting is not suitable for children and women before their periods 882
- First Armenian-German Conference entitled “Heart Failure Spring School” 650
- Obesity: exercising before breakfast helps you lose weight faster 551
- Why do kids usually recover from COVID-19 more easily than adults? 550
- The Conversation: childhood trauma can cause pathological hoarding 548
- Daily Mail: Elderly woman in China gets infected with brain-eating amoeba 543
- Daily Mail: Satiating food reduces cravings for sweets, nutritionist says 513
- Find us on Facebook
- Poll